Grifols (GRFS) announced that its plasma-protein based fibrin sealant, FS, for controlling surgical bleeding has received approval from the United States Food and Drug Administration, FDA, for pediatric patients. The U.S. indication for children and adolescents extends the availability of FS, which is already approved for this patient segment in Europe, in addition to adults. During surgery Grifols FS promotes hemostasis and tissue sealing, resulting in reduced blood loss and potentially fewer complications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Grifols partners with BARDA for PoC testing of ocular immunoglobulin
- Grifols subsidiary GigaGen awarded U.S. BARDA contract
- CNMV initiates disciplinary proceedings against Grifols, Gotham, GIP
- Grifols says sanction not material, won’t impact financial statements
- Grifols says CNMW sanction not material at under EUR 1M